RLFTF News and Press, Mondobiotech Holding AG Basel From 02/14/23

GENEVA, SWITZERLAND / ACCESSWIRE / February 14, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(ORCQB: RLFTY ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company developing and commercializing novel, patent-protected products in select specialty and rare dis...

Relief Therapeutics ( OTCQB:RLFTF )( OTCQB:RLFTY ) said it is planning to list its ordinary shares on the Nasdaq instead of its American depository shares (ADSs). Relief noted that it has decided to voluntarily withdraw a filing submitted to the U.S. Securities and Exchange ...

GENEVA, SWITZERLAND / ACCESSWIRE / February 8, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics), today provided an update on its financing strategy and the decision to voluntarily withdraw its Registration Statement on Form F-1 initially fil...

Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTY ) said it received independent institutional review board (IRB) approval for the protocol of a trial of RLF-TD011 as an adjunctive treatment for patients with cutaneous t-cell lymphoma (CTCL). The Swiss company added that the ...

GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a biopharmaceutical company identifying, developing and commercializing novel, patent protected products in select specialty, rare and ultra-rare disease are...

Despite US FDA approval of Acer Therapeutics' ( NASDAQ: ACER ) Olpruva (sodium phenylbutyrate) for urea cycle disorders, the company's stock is down 33% in Tuesday afternoon trading. The approval triggers the availability of a $42.5M loan term agreement with affiliate...

New FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasda...

GENEVA, SWITZERLAND / ACCESSWIRE / December 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), announced today that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and E...

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements PR Newswire Ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa. , Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding S...

GENEVA, SWITZERLAND / ACCESSWIRE / December 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, r...